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Abstract
Background:  Statins, HMG-CoA reductase inhibitors, are widely prescribed drugs for
dyslipidemias. Recent studies have indicated number of cholesterol independent actions of statins
including their beneficial effects on vascular endothelial dysfunction and memory deficits associated
with dementia of Alzheimer's type. However the potential of statins in dementia of vascular origin
still remains to be explored. Therefore, the present study has been designed to investigate the
effect of Atorvastatin & Pitavastatin on vascular endothelial dysfunction associated memory deficits
in rats. In this study L-Methionine induced vascular dementia was assessed by Morris water-maze
(MWM) test. Biochemical analysis was also performed to unfold possible mechanism of statins
mediated modulation of vascular dementia.
Results: L-Methionine produced endothelial dysfunction as reflected by significant decrease in
serum nitrite concentration. L-Methionine treated rats performed poorly on MWM indicating
impairment of memory as well. These rats also showed a significant rise in brain oxidative stress,
acetylcholinesterase (AChE) activity and serum total cholesterol levels. Both Atorvastatin as well
as Pitavastatin attenuated L-Methionine induced endothelial dysfunction associated memory
deficits. Statins also reversed L-Methionine induced rise in brain oxidative stress, AChE activity and
serum cholesterol.
Conclusion: The beneficial effects of statins may be attributed to their multiple effects and the
study highlights the potential of these drugs in vascular dementia.
Background
Dementia of vascular origin i.e. Vascular dementia (VaD)
has gained much attention in the recent times. After
Alzheimer disease (AD), VaD is the second most common
cause of dementia. In the vascular system, nitric oxide
(NO) generated by endothelial nitric oxide synthase
(eNOS) plays an important role in maintenance of vascu-
lar tone [1]. Hyperhomocysteinemia (Hhcy), or elevation
of plasma total homocysteine, is an important risk factor
for cardiovascular disease, stroke and vascular dementia
[2-4]. Hhcy has been shown to induce endothelial dys-
function by decreasing the bioavailability of NO, and
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increasing vascular oxidative stress [5]. The decreased NO
level has been demonstrated to contribute to the patho-
genesis of dementia [6].
Increased levels of homocysteine have been documented
to produce changes in structure and function of cerebral
blood vessels along with oxidative stress, which play a key
role in cerebral vascular dysfunction [7]. Oxidative stress
and vascular dysfunction are recognized as important
contributing factors in the pathogenesis of AD and other
dementia of vascular origin [6]. In AD and other neurode-
generative diseases, structural deformities in the cerebral
capillaries lead to impairment of cerebral perfusion with
subsequent neuronal dysfunction and death [8]. The well
established risk factors of endothelial dysfunction and
subsequent vascular dementia such as hypertension, his-
tory of stroke, diabetes mellitus and hypercholesterolemia
are all associated with high risk of AD. The noted vascular
dysfunction (vascular deformities) in AD and common
risk factor of AD and VaD suggest a great overlap between
AD and vascular dementia [9]. Moreover, Hhcy has been
documented to increase cholesterol synthesis [10]. Stud-
ies have revealed that in addition to elevated β-amyloid
peptides and ApoE levels, high cholesterol level is another
important risk factor for AD [11].
Only limited therapeutic interventions are available to
reduce the incidence of VaD. Cholinesterase inhibitors,
calcium channel blockers and glutamate antagonists are
few classes of pharmacological agents which are being
clinically explored to reduce symptomatically the impact
of cognitive dysfunction associated with vascular demen-
tia [12]. However, an agent that should improve both
endothelial dysfunction and associated dementia still
need to be explored. Very recently, the focus has been
directed towards statins (HMG-CoA reductase inhibitors),
which are most widely prescribed drugs for dyslipidemias
[13]. Statins in additions to their cholesterol lowering
action are known to possess many cholesterol independ-
ent actions including favorable effect on vascular
endothelium [14]. Moreover, there is an emerging data
indicating that statins exert neuroprotective and antioxi-
dant actions [14]. Statins have been shown to reduce the
risk of ischemic stroke and related memory impairment
by a variety of mechanisms [15]. Epidemiological studies
have suggested that individuals above 50 years of age,
who were receiving statins, had a substantially lowered
risk of developing dementia, independent of the presence
or absence of untreated hyperlipidemia, or exposure to
non-statin lipid-lowering drugs [16]. However, there are
conflicting observations regarding the effect of statins on
cognitive functions. Although, there are a few studies
showing cognitive decline [17], some studies showing no
effect on memory [18,19], yet few studies suggest
improvement of cognitive functions with statin therapy.
Therefore, implication of statins in endothelial dysfunc-
tion and related dementia deserves further investigation.
Results
Effect of Vehicle/Atorvastatin/Pitavastatin/L-Methionine 
on escape latency time (ELT) and time spent in target 
quadrant (TSTQ), using Morris water maze (MWM)
Vehicle treated (0.5%w/v CMC, 10 ml/kg/p.o.) rats
showed a downward trend in their ELT. There was a signif-
icant (p < 0.01) fall in day 4 ELT, when compared to day 1
ELT of these rats (Table 1), reflecting normal learning abil-
ity. Further on day 5 a significant (p < 0.01) rise in TSTQ
was observed, when compared to time spent in other
quadrants (Figure 1), reflecting normal retrieval as well.
Administration of Atorvastatin (10 mg/kg/p.o., 2 weeks
and 4 day)/Pitavastatin (10 mg/kg/p.o., 2 weeks and 4
day) did not show any significant per se effect on ELT and
TSTQ as compared to vehicle treated rats. (Table 1 and
Figure 1) L-Methionine (1.7 g/kg/p.o., 4 weeks and 4 day)
administration produced a significant increase (p < 0.05)
in day 4 ELT, when compared to day 4 ELT of vehicle con-
trol (Table 1) indicating impairment of acquisition. Fur-
ther L-Methionine administration also produced a
significant (p < 0.01) decrease in TSTQ, when compared
TSTQ of vehicle control animals (Figure 1), indicating
impairment of memory as well.
Table 1: Effect of Atorvastatin and Pitavastatin on L-Methionine induced changes in day 4 escape latency time (ELT), using Morris 
Water Maze.
Groups Treatment Dose (kg/day, p.o.) ELT (day 1) in sec ELT (day 4) in sec
I Control 10 ml(0.5%w/w CMC) 81.5 ± 4.5 20.2 ± 2.2a
II L-Methionine 1.7 g 93.8 ± 4.2 49.9 ± 2.4b
III Atorvastatin per se 10 mg 85.5 ± 4.1 22.4 ± 3.4
IV Pitavastatin per se 10 mg 82.3 ± 4.3 21.3 ± 3.8
V L-Methionine + Atorvastatin 10 mg 81.9 ± 3.9 27.0 ± 2.4c
VI L-Methionine + Pitavastatin 10 mg 82.5 ± 4.4 27.9 ± 3.6c
Each group (n = 10), represent mean ± SEM.
a = p < 0.01 Day 1 Vs Day 4 ELT in vehicle control.
b = p < 0.05 Vs Day 4 ELT in vehicle control.
c = p < 0.05 Vs Day 4 ELT in L-Methionine treated group.BMC Pharmacology 2008, 8:14 http://www.biomedcentral.com/1471-2210/8/14
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Effect of Atorvastatin/Pitavastatin on L-Methionine 
induced impairment of learning and memory using Morris 
water maze
Administration of Atorvastatin (10 mg/kg/p.o., 2 weeks
and 4 day), Pitavastatin (10 mg/kg/p.o., 2 weeks and 4
day), significantly (p  < 0.05) prevented L-Methionine
induced rise in day 4 ELT, indicating reversal of L-methio-
nine induced impairment of acquisition (Table 1). Fur-
ther treatment of these drugs also attenuated L-
Methionine induced decrease in day 5 TSTQ in a signifi-
cant manner (p < 0.05), indicating reversal of L-methio-
nine induced impairment of memory (Figure 1).
Effect of Atorvastatin/Pitavastatin on L-Methionine 
induced change in endothelium dependent relaxation
Acetylcholine (ACh) and sodium nitroprusside (SNP) in a
dose dependent manner produced endothelium depend-
ent and independent relaxation in phenylephrine (3 × 10-
6 M) precontracted isolated rat aortic ring preparation. L-
methionine (1.7 g/kg/p.o., 4 weeks and 4 day) administra-
tion significantly (p  < 0.05) attenuated acetylcholine
induced endothelium dependent relaxation (Figure 2),
however it did not affect SNP induced endothelium inde-
pendent relaxation (Figure 3). Treatment of Atorvastatin
(10 mg/kg/p.o., 2 weeks and 4 day), Pitavastatin (10 mg/
kg/p.o., 2 weeks and 4 day), significantly (p < 0.05) abol-
ished the effect of L-Methionine on endothelial depend-
ent relaxation. Further Atorvastatin and Pitavastatin did
not show any per se effect on endothelium dependent
relaxation.
Effect of Atorvastatin/Pitavastatin on L-Methionine 
induced change in serum homocysteine level
Administration of L-Methionine (1.7 g/kg/p.o., 4 weeks
and 4 day), produced a significant (p < 0.01) increase in
serum homocysteine, when compared to vehicle treated
rats. Treatment with Atorvastatin (10 mg/kg/p.o., 2 weeks
Effect of Atorvastatin and Pitavastatin on L-Methionine  induced changes in day 5 Time Spent in Target quadrant  (TSTQ), using Morris Water Maze Figure 1
Effect of Atorvastatin and Pitavastatin on L-Methio-
nine induced changes in day 5 Time Spent in Target 
quadrant (TSTQ), using Morris Water Maze. (L-Meth 
= L-Methionine; Atorva = Atorvastatin; Pitava = Pitavastatin). 
Each group (n = 10), represent mean ± SEM. a = p < 0.05 
Time Spent in Q1, Q2, Q3, Quadrant Vs Q4 quadrant in 
Control. b = p < 0.05 Vs Time Spent in Target Quadrant Q4 
of Control. c = p < 0.05 Vs Time Spent in Target Quadrant 
Q4 of L-Methionine treated.
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Effect of Atorvastatin/Pitavastatin on L-Methionine change in  endothelium dependent relaxation using isolated rat aortic  ring preparation Figure 2
Effect of Atorvastatin/Pitavastatin on L-Methionine 
change in endothelium dependent relaxation using 
isolated rat aortic ring preparation. (L-Meth = L-
Methionine; Atorva = Atorvastatin; Pitava = Pitavastatin). 
Each group (n = 10), represent mean ± SEM. Responses are 
expressed as % of maximum contraction induced by phenyle-
phrine (3 × 10-6 M). a = p < 0.05 Vs Control. b = p < 0.05 Vs 
L-Methionine treated group.
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Effect of Atorvastatin/Pitavastatin/L-Methionine induced on  sodium nitroprusside induced endothelium independent  relaxation using isolated rat aortic ring preparation Figure 3
Effect of Atorvastatin/Pitavastatin/L-Methionine 
induced on sodium nitroprusside induced endothe-
lium independent relaxation using isolated rat aortic 
ring preparation. (L-Meth = L-Methionine; Atorva = Ator-
vastatin; Pitava = Pitavastatin). Each group (n = 10), represent 
mean ± SEM. Responses are expressed as % of maximum 
contraction induced by phenylephrine (3 × 10-6 M).
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and 4 day)/Pitavastatin (10 mg/kg/p.o., 2 weeks and 4
day) produced a significant (p  < 0.05) reduction of L-
methionine induced rise in serum homocysteine level
(Table 2). Further, Atorvastatin (10 mg/kg/p.o., 2 weeks
and 4 day)/Pitavastatin (10 mg/kg/p.o., 2 weeks and 4
day) did not show any significant per se effect on serum
homocysteine level (Table 2).
Effect of Atorvastatin/Pitavastatin on L-Methionine 
induced change in serum nitrite level
Administration of L-Methionine (1.7 g/kg/p.o., 4 weeks
and 4 day), produced a significant (p < 0.01) decrease in
serum nitrite, when compared to vehicle treated rats.
Treatment with Atorvastatin (10 mg/kg/p.o., 2 weeks and
4 day)/Pitavastatin (10 mg/kg/p.o., 2 weeks and 4 day)
prevented L-methionine induced decrease in serum nitrite
level in a significant (p < 0.05) manner (Figure 4). Further,
Atorvastatin (10 mg/kg/p.o., 2 weeks and 4 day)/Pitavas-
tatin (10 mg/kg/p.o., 2 weeks and 4 day) did not show any
significant per se effect on serum nitrite level (Figure 4).
Effect of Atorvastatin/Pitavastatin/L-Methionine induced 
change in total serum cholesterol levels
Administration of L-Methionine (1.7 g/kg/p.o., 4 weeks
and 4 day) produced a significant (p < 0.05), increase in
total serum cholesterol levels of animals, when compared
to vehicle control. Treatment with Atorvastatin (10 mg/
kg/p.o., 2 weeks and 4 day)/Pitavastatin (10 mg/kg/p.o., 2
weeks and 4 days) attenuated L-Methionine induced rise
in total serum cholesterol levels in a significant (p < 0.05)
manner (Figure 5). Furthermore Atorvastatin (10 mg/kg/
p.o., 2 weeks and 4 day)/Pitavastatin (10 mg/kg/p.o., 2
weeks and 4 day) did not show any significant per se effect
on total serum cholesterol levels (Figure 3), when com-
pared to vehicle control group (Figure 5).
Effect of Atorvastatin/Pitavastatin on L-Methionine 
induced change in brain acetyl cholinesterase (AChE) 
activity
Administration of L-Methionine (1.7 g/kg/p.o., 4 weeks
and 4 day) produced a significant (p < 0.05), increase in
brain AChE activity, when compared to vehicle treated
rats. Treatment with Atorvastatin (10 mg/kg/p.o., 2 weeks
and 4 day)/Pitavastatin (10 mg/kg/p.o., 2 weeks and 4
day) significantly (p  < 0.05), prevented L-Methionine
induced rise in brain AChE activity. Further Atorvastatin
(10 mg/kg/p.o., 2 weeks and 4 day)/Pitavastatin (10 mg/
kg/p.o., 2 weeks and 4 day) did not show any significant
per se effect on brain AChE activity (Figure 6).
Effect of Atorvastatin/Pitavastatin on L-Methionine 
induced change in oxidative stress levels of brain
Administration of L-Methionine (1.7 g/kg/p.o., 4 weeks
and 4 day), produced a significant increase (p < 0.05), in
brain thiobarbituric acid reactive species (TBARS) level
(Figure 7) and a decrease (p < 0.01), in the level of reduced
form of glutathione (GSH) (Figure 8), when compared to
vehicle treated rats; hence reflecting induction of oxidative
stress. Treatment with Atorvastatin (10 mg/kg/p.o., 2
weeks and 4 day)/Pitavastatin (10 mg/kg/p.o., 2 weeks
and 4 day) significantly (p < 0.05) prevented L-Methio-
nine induced oxidative stress (Figure 7, 8). Further Atorv-
astatin (10 mg/kg/p.o., 2 weeks and 4 day)/Pitavastatin
(10 mg/kg/p.o., 2 weeks and 4 day) did not show any sig-
nificant per se effect on oxidative stress level (Figure 7, 8).
Discussion
Young male rats were employed in the present study, as it
is reported that aging and consequent variation of estro-
gen in blood modulates the activity of endothelial nitric
oxide synthase (eNOS), which further affects the function
of vascular endothelium and memory [20,21]. Morris
Water Maze test employed in present study is one of the
most widely accepted models to evaluate learning and
memory of the animals [22,23]. Nitric oxide (NO) synthe-
sized in the endothelium and its levels get attenuated dur-
ing endothelial dysfunction. Endogenously formed NO is
highly unstable and gets converted to nitrate and nitrite
[24]. Therefore, serum nitrite concentration has been
employed as specific a marker of endothelial dysfunction
[5].
A significant decrease in escape latency time (ELT day 4)
of control animals during ongoing acquisition trials
Table 2: Effect of Atorvastatin and Pitavastatin on L-Methionine induced changes in Serum homocysteine.
Groups Treatment Dose (kg/day, p.o.) Serum homocysteine (μM)
I Control 10 ml(0.5%w/w CMC) 4.23 ± 0.15
II L-Methionine 1.7 g 20.8 ± 0.84a
III Atorvastatin per se 10 mg 3.95 ± 0.21
IV Pitavastatin per se 10 mg 3.92 ± 0.23
V L-Methionine + Atorvastatin 10 mg 12.9 ± 0.38b
VI L-Methionine + Pitavastatin 10 mg 13.5 ± 0.34b
Each group (n = 10), represent mean ± SEM.
a = p < 0.01 Vs serum homocysteine level of Control.
b = p < 0.05 Vs serum homocysteine level of L-Methionine treated group.BMC Pharmacology 2008, 8:14 http://www.biomedcentral.com/1471-2210/8/14
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denoted normal acquisition of memory and an increase in
time spent in target quadrant (TSTQ), in search of missing
platform during retrieval trial indicated, retrieval of mem-
ory. These results are consistent to our earlier findings and
reports from other laboratory [13,25,26].
L-Methionine treatment for 4 weeks, in the present study
significantly raised serum homocysteine level, decreased
serum nitrite levels and markedly attenuated acetylcho-
line induced endothelium dependent relaxation, there-
fore, reflecting endothelial dysfunction. Further L-
methionine administration also produced a significant
impairment of acquisition and retrieval of memory as
reflected by decreased Morris water-maze performance.
Moreover, an enhancement of brain acetyl cholinesterase
Effect of Atorvastatin and Pitavastatin on L-Methionine  induced changes in serum nitrite level Figure 4
Effect of Atorvastatin and Pitavastatin on L-Methio-
nine induced changes in serum nitrite level. (L-Meth = 
L-Methionine; Atorva = Atorvastatin; Pitava = Pitavastatin). 
Each group (n = 10), represent mean ± SEM. a = p < 0.01 Vs 
serum nitrite of Control. b = p < 0.05 Vs serum nitrite of L-
Methionine treated group.
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Effect of Atorvastatin and Pitavastatin on L-Methionine  induced changes in serum total cholesterol level Figure 5
Effect of Atorvastatin and Pitavastatin on L-Methio-
nine induced changes in serum total cholesterol level. 
(L-Meth = L-Methionine; Atorva = Atorvastatin; Pitava = 
Pitavastatin). Each group (n = 10), represent mean ± SEM. a = 
p < 0.05 Vs serum total cholesterol of Control. b = p < 0.05 
Vs serum total cholesterol of L-Methionine treated.
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Effect of Atorvastatin and Pitavastatin on L-Methionine  induced changes brain acetylcholinesterase (AChE) activity Figure 6
Effect of Atorvastatin and Pitavastatin on L-Methio-
nine induced changes brain acetylcholinesterase 
(AChE) activity. (L-Meth = L-Methionine; Atorva = Atorv-
astatin; Pitava = Pitavastatin). Each group (n = 10), represent 
mean ± SEM. a = p < 0.05 brain AChE activity of Control. b = 
p < 0.05 Vs brain AChE activity of L-Methionine treated.
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Effect of Atorvastatin and Pitavastatin on L-Methionine  induced changes in brain thiobarbituric acid reactive species  (TBARS) level Figure 7
Effect of Atorvastatin and Pitavastatin on L-Methio-
nine induced changes in brain thiobarbituric acid 
reactive species (TBARS) level. (L-Meth = L-Methionine; 
Atorva = Atorvastatin; Pitava = Pitavastatin). Each group (n = 
10), represent mean ± SEM. a = p < 0.01 brain TBARS level 
of Control. b = p < 0.05 Vs brain TBARS level of L-Methio-
nine treated group.
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(AChE) activity, increase in brain oxidative stress (as
reflected by rise in brain TBARS and fall in GSH levels)
and increase in serum total cholesterol levels were also
observed. Recently, it has been reported that chronic
experimental hyperhomocysteinemia produce cognitive
dysfunction [27,28], and increase in brain AChE activity
[29]. L-Methionine induced hyperhomocysteinemia is a
well established model of experimental endothelial dys-
function [30,31]. Hyperhomocysteinemia has been
reported to induce endothelial dysfunction by decreasing
the bioavailability of NO and by increasing vascular oxi-
dative stress [5]. Our observation also supports above
contention, as a significant fall in serum nitrite levels
along with rise in oxidative stress levels (increase TBARS
and decrease GSH) were noted in L-methionine treated
rats.
The increased level of homocysteine has been reported to
produce change in structure and function of cerebral
blood vessels along with oxidative stress, which play a key
role in cerebral vascular dysfunction [7]. Several lines of
evidences have strongly advocated a direct relationship
between vascular endothelial dysfunction and dementia
better known as vascular dementia [32,33]. Cerebral vas-
cular endothelial dysfunction has also been shown to
enhance progression of dementia of Alzheimer disease
(AD) [33]. Enhanced levels of brain AChE activity and oxi-
dative stress have also been noted in patients suffering
form dementia of AD and other dementias [34].
Further hyperhomocysteinemia has also been shown to
be neurotoxic, and the neurotoxicity may be due to over
activation of N-methyl-D-aspartate receptors or by
enhanced vulnerability of hippocampal neuron to excito-
toxic insults and amyloid β-peptide toxicity [35,36].
Moreover, methionine rich diet in rats has been demon-
strated to enhance cholesterol concentration in the
plasma and liver [10]. Several studies have also revealed
high serum cholesterol level as another important risk fac-
tor of AD [37]. Therefore L-Methionine induced memory
dysfunction in the present study may be attributed to its
multiple effects i.e. decrease in serum nitrite level
(endothelial dysfunction), rise in oxidative stress level,
enhancement of brain AChE activity, serum total choles-
terol as well as direct neurotoxicity.
In the present study, treatment with Atorvastatin and
Pitavastatin significantly improved L-Methionine induced
endothelial dysfunction manifested in the terms of
endothelium dependent relaxation; increased serum
nitrite levels, decreased serum homocysteine, and
decreased oxidative stress (decrease TBARS and increase
GSH). Statins, in addition to their cholesterol lowering
action has been reported to exert number of cholesterol
independent actions i.e. pleotropic actions. Statins have
been demonstrated to enhance the expression of eNOS in
human endothelial cells [38]. They have been known to
activate Akt/protein kinase B, which subsequently acti-
vates eNOS [39]. Studies with Atorvastatin and Simvasta-
tin have shown to inhibit the expression of prepro-
endothelin (ET)-1 mRNA and reduce plasma ET-1 levels,
endothelin being a potent vasoconstricting agent [40].
Furthermore, statins appear to inhibit the synthesis of iso-
prenoids, compounds that are required for the posttrans-
lational modification of important signaling molecules
such as Rho, Rac, and Ras [41]. Inhibition of Rho activa-
tion has been shown to increase endothelial NO produc-
tion [38] and reduces ET-1 expression [40]. Recently,
Atorvastatin has been documented to improve the func-
tion of endothelium by lowering the expression of
p22phox and production of reactive oxygen species
[30,42]. Further, in another recent report it has been indi-
cated that hyperhomocysteinemia induce impairment of
NO production through the modulation of Cav-1 expres-
sion associated with a loss of eNOS in caveolae [43]. Stat-
ins have been shown to prevent the expression of
caveolin, a negative regulator of eNOS [44]. Therefore
Atorvastatin and Pitavastatin induced improvement of
endothelial dysfunction in our study may be attributed to
their stimulatory effect on endothelial nitric oxide pro-
duction and their antioxidative action.
Further, administration of Atorvastatin/Pitavastatin in the
present investigation also, reversed memory deficit
induced by L-Methionine (hyperhomocysteinemia). Sev-
eral recent clinical reports have suggested that the net
brain cholesterol concentration is regulated by serum cho-
lesterol level and there is a cross talk between the CNS and
Effect of Atorvastatin and Pitavastatin on L-Methionine  induced changes in brain reduced glutathione (GSH) level Figure 8
Effect of Atorvastatin and Pitavastatin on L-Methio-
nine induced changes in brain reduced glutathione 
(GSH) level. (L-Meth = L-Methionine; Atorva = Atorvasta-
tin; Pitava = Pitavastatin). Each group (n = 10), represent 
Mean ± SEM. a = p < 0.01 brain GSH level of Control. b = p 
< 0.05 Vs brain GSH level of L-Methionine treated group.
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peripheral cholesterol pools [45,46]. Cholesterol turnover
appears to play a crucial role in the deposition and clear-
ance of amyloid peptide in brain and ApoE is a cholesterol
transporting protein that is associated with amyloid
deposits [47,48]. Further, serum cholesterol, atherosclero-
sis, apolipoprotein-E and AD all appear to be intercon-
nected [49,50]. Studies involving cultured rat cortical
neurons have revealed neuroprotective action of Atorvas-
tatin against glutamate induced excitotoxicity [51].
In our recent studies, we have reported that Atorvastatin,
Simvastatin and Pitavastatin reversed memory deficits of
rats and mice associated with dementia of AD type and
memory improving effects of these statins mediated
through their cholesterol dependent and in dependent
actions [13,25]. Furthermore, statins have also been
shown to exert beneficial effects in cerebral ischemia and
stroke providing neuroprotection via enhancement of NO
production [52].
Many studies, in the recent years have implicated a vital
role for NO in neurophysiological process of learning and
memory [53]. Inhibition of NO system impaired memory
in rats [54,55]. Whereas, stimulation of NO production
improved cognitive functions in Alzheimer patients [56].
NO, donors like molsidomine reversed scopolamine
induced amnesia in rats [57]. NO probably, acts as retro-
grade messenger in the formation of long term potentia-
tion (LTP) at the molecular level of learning and memory
processes [58]. Therefore, Atorvastatin and Pitavastatin in
present investigation appear to reverse L-Methionine
induced memory deficits via multiple actions viz; decrease
in total cholesterol, brain oxidative stress (decrease TBARS
and increase GSH) levels, AChE activity and increase in
serum nitrite levels. Nevertheless, further studies incorpo-
rating female rats as well as other species of animals such
as mice, using different memory model (other than Mor-
ris water-maze), duly supported by histopathology of
brain tissue are required in order to support and extend
potential of these statins in endothelial dysfunction
related memory deficits.
Conclusion
It may be concluded that chronic L-Methionine adminis-
tration (hyperhomocysteinemia) has produced endothe-
lial dysfunction along with impairment of learning and
memory (vascular dementia). Atorvastatin and Pitavasta-
tin exerted beneficial effects on endothelial dysfunction
and related memory deficits by virtue of their cholesterol
dependent as well as cholesterol independent actions.
Perhaps this is the first report highlighting potential of
Statins in L-Methionine induced endothelial dysfunction
associated memory deficits.
Methods
Animals
Age matched (six months old) male Wistar Albino rats,
weighing 150–200 g were employed in the present study.
Animals were procured from Institute of Veterinary Sci-
ence, Izat-Nagar Bareilly (U.P), India. Rats were provided
standard laboratory feed (Kisan Feeds Ltd, Chandigarh,
India) and tap water ad libitum and were exposed to 12 h
light and 12 h dark cycle. The animals were acclimatized
to the laboratory condition before experiments. The
experimental protocol was duly approved by Institutional
Animal Ethics Committee (IAEC) and care of the animals
was taken as per guidelines of the Committee for the Pur-
pose of Control and Supervision of Experiments on Ani-
mals (CPCSEA), ministry of Environment and Forests,
Government of India, (Reg. No. 107/1999/CPCSEA).
Drugs and Chemicals
Atorvastatin was a gift from Ind swift Ltd., Mohali, Pun-
jab, India. Pitavastatin was a gift from Zydus Research
Center, Ahmedabad, Gujarat, India. All other reagents
purchased from Merck limited, Mumbai, India, SD fine-
chemicals limited, Mumbai, India, Loba Chem, Mumbai,
India and Sigma-Aldrich, USA. Atorvastatin, Pitavastatin
and L-Methionine were suspended in 0.5% w/v of carboxy
methyl cellulose (CMC).
L-Methionine Induced endothelial dysfunction and 
Vascular Dementia
Rats, were administered L-Methionine (1.7 g/kg/day, p.o.)
for 4 weeks to produce hyperhomocysteinemia-induced
endothelial dysfunction [30]. Assessment of vascular
endothelial function was carried out by measuring acetyl-
choline induced endothelium dependent relaxation and
sodium nitroprusside induced endothelium independent
relaxation using isolated aortic ring preparation according
to the method of Pieper [59] together with estimation of
serum nitrite concentration.
Body weight of rats was monitored weekly. After 4 weeks,
rats were subjected to Morris water maze test for the eval-
uation of their memory status. The L-Methionine treat-
ment was continued during acquisition trials on Morris
Water Maze.
Morris Water Maze Test
Morris Water Maze (MWM) test was employed to assess
learning and memory of rats [22,23]. The MWM proce-
dure was based on a principle, where the animals were
placed in a large pool of water, as animals dislike swim-
ming, their tendency was to escape from the water being
accomplished by finding an escape platform. MWM con-
sisted of large circular pool (150 cm in diameter, 45 cm in
height), filled to a depth of 30 cm with water at 28 ± 1°C.BMC Pharmacology 2008, 8:14 http://www.biomedcentral.com/1471-2210/8/14
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The water was made opaque with non-toxic white colored
dye. The tank was divided hypothetically, into four equal
quadrants with help of two threads, fixed at right angle to
each other on the rim of the pool. A submerged platform
(10 cm2), painted in white was placed inside the target
quadrants of this pool, 1 cm below surface of water. The
position of platform was kept unaltered throughout the
training session. Each animal was subjected to four con-
secutive trials on each day with gap of 5 min. The rat was
gently placed in the water of the pool between quadrants,
facing the wall of pool with drop location changing for
each trial, and allowed 120 sec to locate submerged plat-
form. Then, it was allowed to stay on the platform for
another 20 sec. If it failed to find the platform within 120
sec, it was guided gently onto platform and allowed to
remain there for 20 sec. Escape latency time (ELT) to
locate the hidden platform in water maze was noted as an
index of acquisition or learning. Animal was subjected to
four acquisition trials daily for four consecutive days. On
fifth day, the platform was removed and each rat was
allowed to explore the pool for 120 sec. Mean time spent
in all four quadrants was noted. The mean time spent by
the animal in target quadrant searching for the hidden
platform was noted as an index of retrieval.
Acquisition Trial
Each rat was subjected to four trials on each day. A rest
period of 5 min was allowed in between each trial. Four
trials per day were repeated for four consecutive days.
Starting position on each day to conduct four acquisition
trials was changed as described below and Q4 was main-
tained as target quadrant in all acquisition trials. Mean
escape latency time (ELT) calculated for each day during
acquisition trials and day 4 ELT was used as an index of
acquisition (table 3).
Retrieval Trial
On fifth day the platform was removed. Rat was placed in
water maze and allowed to explore the maze for 120 sec.
Each rat was subjected to four such trials and each trial
was started from different quadrant. Mean time spent in
all three quadrants i.e. Q1, Q2 and Q3 were recorded and
the time spent in the target quadrant i.e. Q4 in search of
missing platform provided an index of retrieval. The
experimenter always stood at the same position. Care was
taken not to disturb the relative location of water maze
with respect to other objects in the laboratory serving, as
prominent visual clues. All the trials were completed
between 09.00 to 17.00 hrs in semi sound proof labora-
tory.
Biochemical Parameters
Collection of sample
The animals were sacrificed by cervical dislocation; tho-
racic aorta and brain tissue were carefully removed. Tho-
racic aorta was used for endothelium dependent and
independent relaxation, whereas brain tissue was sub-
jected to various biochemical estimations.
The removed brains were homogenized in phosphate
buffer (pH 7.4, 10% w/v) using Teflon homogenizer. The
clear supernatant, obtained after centrifugation at 3000
rpm for 15 min, was used to estimate acetyl cholinesterase
(AChE) activity, thiobarbituric acid reactive species
(TBARS), reduced glutathione (GSH) and protein content.
Blood samples for biochemical estimation were collected
just before sacrificing the rats. The blood was kept at room
temperature for 30 min and then centrifuged at 4000 rpm
for 15 min to separate serum. Serum was used to estimate
serum homocysteine, serum nitrite concentration and
total serum cholesterol.
Estimation of serum homocysteine
Determination of homocysteine was carried out using
HPLC (Varian Inc., CA, USA) attached with fluorescent
HPLC detector according to the method of Dimitrova et al
[60]. 100 μl of serum sample was added to 1.5 ml eppen-
dorff containing 10 μl of water and 5 μl of n-amyl alcohol
and was gently vortexed. 35 μl of sodium borohydrate rea-
gent (35 μl of 1.43 M sodium borohydride in 0.1 M
sodium hydroxide), 35 μl of 1 M of hydrochloric acid and
50 μl of 10 mM monobromobimane in 4 M sodium EDTA
(pH 7) were added to eppendorff tube containing serum
sample, capped, mixed and incubated at 42°C for 12 min.
Then, it was cooled, vortexed and maintained at RT for 10
min. The sample was centrifuged at 12,200 g for 10 min
to remove protein, acidic clear supernatant was separated
and supernatant was adjusted to pH 4 using 25 μl of 2 M
Tris-HCL. The sample was then centrifuged at 12,200 g for
1 min and 100 μl of supernatant was aliquoted for HPLC
analysis.
A fixed volume autosampler was used to inject 20 μl of
sample into 4.6 × 250 mm RP8 ultrasphere column
equipped with brownlee RP 18 new guard column. The
solvent mixture in ratio of 94.75: 5: 0.25 of water: metha-
nol: acetic acid was maintained at pH 3.4 using 5 M
NaOH in pump A and 100% methanol was maintained in
pump B. The injection rate of sample was maintained at 2
ml per min. HPLC detector was set with excitation wave-
length at 390 nm and emission wavelength at 418 nm.
Table 3: Mean escape latency time (ELT) calculated for each day 
during acquisition trials and day 4 ELT was used as an index of 
acquisition
Day1 Q1 Q2 Q3 Q4
Day2 Q2 Q3 Q4 Q1
Day3 Q3 Q4 Q1 Q2
Day4 Q4 Q1 Q2 Q3BMC Pharmacology 2008, 8:14 http://www.biomedcentral.com/1471-2210/8/14
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The sensitivity range and rise time of detector were set at
0.1 sec and 2 sec respectively. The calibration curve for
homocysteine as homocysteine-S-bimane was plotted
using 100 μl quality control serum fortified with 10 μl
homocysteine (1–1000 μM) solution. The data of calibra-
tion curve were regressed and the curve was used to calcu-
late serum concentration of homocysteine.
Rats with serum homocysteine levels of > 10 μM were con-
sidered to be hyperhomocysteinemic.
Estimation of serum nitrite concentration
Serum nitrite concentration was estimated using method
of Sastry et al. [24]. 400 μl of carbonate buffer (pH 9.0)
was added to 100 μl of serum or standards sample fol-
lowed by addition of small amount (~0.15 g) of copper-
cadmium alloy. The tubes were incubated at room tem-
perature for 1 h to reduce nitrate to nitrite. The reaction
was stopped by adding 100 μl of 0.35 M sodium hydrox-
ide. Following this, 400 μl of zinc sulfate solution (120
mM) was added to deproteinate the serum samples. The
samples were allowed to stand for 10 min and then cen-
trifuged at 4000 g for 10 min. Greiss reagent (250 μl of
1.0% sulfanilamide prepared in 3 N HCl and 250 μl of
0.1% N-naphthylethylenediamine prepared in water) was
added to aliquots (500 μl) of clear supernatant and serum
nitrite was measured spectrophotometrically (DU 640B
Spectrophotometer, Beckman Coulter Inc., CA, USA) at
545 nm. The standard curve of sodium nitrite (5 to 50
μM) was plotted to calculate concentration of serum
nitrite.
Estimation of total cholesterol
Total serum cholesterol was estimated spectrophotometri-
cally (DU 640B spectrophotometer, Beckman Coulter
Inc., CA, USA) at 540 nm by CHOP/POD-phosphotung-
state enzymatic method [61] using commercially availa-
ble conventional diagnostic kit (Monozyme India ltd.,
Secundrabad).
Estimation of brain acetyl cholinesterase (AChE) activity
The whole brain AChE activity was measured by the
method of Ellman et al [62] with slight modifications
[63]. This was measured on the basis of the formation of
yellow colour due to the reaction of thiocholine with
dithiobisnitrobenzoate ions. The rate of formation of thi-
ocholine from acetylcholine iodide in the presence of
brain cholinesterase was measured using a spectropho-
tometer. 0.5 ml of supernatant liquid of the brain
homogenate was pipetted out into 25 ml volumetric flask
and dilution was made with a freshly prepared DTNB
{5,5'-dithiobis (2-nitro benzoic acid)} solution (10 mg
DTNB in 100 ml of sorenson phosphate buffer, pH 8.0).
From the volumetric flask, two 4 ml portions were pipet-
ted out into two test tubes. Into one of the test tube, 2
drops of eserine solution was added. 1 ml of substrate
solution (75 mg of acetylcholine iodide per 50 ml of dis-
tilled water) was pipetted out into both of the test tubes
and incubated for 10 min. at 30°C. The solution contain-
ing eserine solution was used for zeroing the colorimeter
and change in absorbance per min. of the sample was read
spectrophotometrically (DU 640B spectrophotometer,
Beckman Coulter Inc., CA, USA) at 420 nm. AChE activity
was calculated using the following formula:
Where R = rate of enzyme activity in 'n' mole of acetylcho-
line iodide hydrolyzed/minute/mg protein
δO.D. = Change in absorbance/minute
E = Extinction coefficient = 13600/M/cm
Estimation of brain thiobarbituric acid reactive species (TBARS) level
The whole brain TBARS level was measured by the
method of Ohokawa et al [64] with slight modifications.
0.2 ml brain homogenate was pipetted out in a test tube,
followed by addition of 0.2 ml sodium dodecyl sulphate
(SDS), 1.5 ml of 30% acetic acid (pH-3.5), 1.5 ml of 0.8%
thiobarbituric acid (TBA) and make up the volume up to
4.0 ml with distilled water (DW). The test tubes were incu-
bated at 95°C for 60 min., and then cool it. 1.0 ml of DW
and 5.0 ml of n-butanol: pyridine (15: 1 v/v) mixture was
added to the test tubes and centrifuged at the 4,000 × g for
10 min. The absorbance of developed colour in organic
layer was Measured spectrophotometrically at 532 nm
(DU 640B spectrophotometer, Beckman Coulter Inc., CA,
USA). The absorbance from a standard curve generated
using 1,1,3,3, tetra-methoxy propane as standard (range =
1 nmol – 10 nmol) was extrapolated.
Estimation of brain reduced glutathione (GSH) level
The whole brain GSH level was measured by the method
of Beutler et al [65] with slight modifications. Tissue
homogenate was taken and the proteins were precipitated
with 10% w/v chilled trichloroacetic acid. Samples were
kept in ice bath and were centrifuged after 30 min. at 1000
× g for 10 min. at 4°C. GSH levels were measured in the
supernatant. 0.5 ml supernatant was mixed with 2.0 ml of
0.3 M disodium hydrogen phosphate solution and 0.25
ml of freshly prepared DTNB {5,5'-dithiobis (2-nitro ben-
zoic acid)} solution (40 mg/100 ml in 1% w/v sodium cit-
rate) was added just before measuring the absorbance
spectrophotometrically at 412 nm (DU 640B spectropho-
tometer, Beckman Coulter Inc., CA, USA). Different con-
centration of GSH standard was also processed similarly
to prepare a standard curve (5–50 μg) simultaneously.
R
 OD Volume of Assay   ml
E mg of protein
=
×
×
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Results have been expressed as n mole of GSH/mg of pro-
tein.
Estimation of brain total protein
For the estimation of total protein in brain, method of
Lowry et al [66] with slight modifications was used. 150
μL of supernatant was taken in a test tube, volume was
made up to 1 ml with distilled water than 5 ml of Lowry's
reagent (freshly prepared mixture of 1% w/v copper sul-
phate, 2% w/v sodium potassium tartrate and 2% w/v
sodium carbonate in 0.1 N NaOH in the ratio of 1:1:98
respectively), was added and mixed thoroughly. Mixture
was allowed to stand for 15 minutes at room temperature
and then 0.5 ml of 1:1 v/v diluted Folin-Ciacalteu reagent
was added. Contents were vortexed and incubated at
37°C for 30 minutes. Then absorbance was determined
spectrophotometrically at 750 nm (DU 640B spectropho-
tometer, Beckman Coulter Inc., CA, USA) against suitably
prepared blank. A standard curved using 25–200 mg of
BSA was plotted. The amount of total protein was
expressed in mg.
Experimental Design
Six groups, each group comprised 10 albino Wistar rats,
were employed in the present study.
Group I (Vehicle treated control)
Rats were administered 0.5% w/v CMC (10 ml/kg/day,
p.o.) for 4 weeks and then subjected to MWM test. The
vehicle was also administered 45 min before acquisition
trial conducted from day 1 to day 4 and retrieval trial con-
ducted on day 5.
Group II (L-Methionine treated)
In order to induce hyperhomocysteinemia, the rats were
administered L-methionine (1.7 g/kg/day, p.o.) for 4
weeks and then subjected to MWM test. The treatment of
L-Methionine was continued (administered 45 min
before) during acquisition trial conducted from day 1 to
day 4. The animals were administered vehicle (0.5%w/v
CMC, 10 ml/kg, p.o.) 45 min before retrieval trial con-
ducted on day 5.
Group III (Atorvastatin per se)
Rats were administered Atorvastatin (10 mg/kg/day, p.o.)
for 2 weeks and then subjected to MWM test. The treat-
ment was continued (administered 45 min before) during
acquisition trial conducted from day 1 to day 4. The ani-
mals were administered vehicle (0.5%w/v CMC, 10 ml/
kg, p.o) 45 min before retrieval trial conducted on day 5.
Group IV (Pitavastatin per se)
Rats were administered Pitavastatin (10 mg/kg/day, p.o.)
for 2 weeks and rest of protocol was same as mentioned in
group III.
Group V (L-Methionine + Atorvastatin treated)
The hyperhomocysteinemic rats were treated with Atorv-
astatin (10 mg/kg/day, p.o.) for 2 weeks (3rd and 4th week
of L-Methionine administration) and then subjected to
MWM test. The co-administration of Atorvastatin and L-
Methionine was continued (administered 45 min before)
during acquisition trial conduct from day 1 to day 4. The
animals were administered vehicle (0.5%w/v CMC, 10
ml/kg, p.o) 45 min before retrieval trial conducted on day
5.
Group VI (L-Methionine + Pitavastatin treated)
The hyperhomocysteinemic rats were treated with Pitavas-
tatin (10 mg/kg/day, p.o.) and subjected to MWM test as
described in group VI.
Statistical analysis
The results were expressed as mean ± standard error of
means (S.E.M.) The data for isolated aortic ring prepara-
tion was statistically analyzed using repeated measure
ANOVA followed by Newman-Keul's test. Rest of the data
obtained from various groups was statistically analyzed
using one-way ANOVA followed by Tukey's Multiple
Range test. The p < 0.05 was considered to be statistically
significant.
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